# Official Website: CaLycia Biosciences

**Type:** source
**Status:** Useful
**Confidence:** Medium
**Source Type:** Official Website
**URL:** https://www.calyciabioscience.com
**Publisher:** CaLycia Bioscience
**Accessed:** 2026-06-19
**Updated:** 2026-06-19

## Summary

CaLycia Bioscience's official website describes a Salt Lake City biotechnology company developing macrophage cell therapies for central nervous system solid tumors, with local intracranial delivery designed to bypass blood-brain-barrier limits. The site outlines a four-step platform (engineer, infiltrate, remodel, scale) and a pipeline led by CALYM-001 for glioblastoma at pre-IND stage.

## Useful Claims

- The company describes itself as a **Salt Lake City-based biotechnology company** developing novel **macrophage cell therapies** for the central nervous system.
- The thesis is that engineered macrophages can **infiltrate, remodel, and treat aggressive solid tumors of the brain**, leveraging macrophage biology rather than systemic T-cell approaches.
- **Local administration into the brain** is the stated delivery strategy, bypassing systemic barriers including the blood-brain barrier and immunosuppressive intracranial tumor microenvironments.
- Four mechanism pillars are listed: **local delivery** (direct CNS administration), **innate migration** (macrophage motility through tissue margins), **phagocytic clearance** (engulfment and destruction of tumor cells), and **antigen presentation** (local tumor-antigen processing to recruit adaptive immunity).
- The **platform process** is described as: (1) engineer patient macrophages with targeting receptors and immune-activating payloads, (2) infiltrate via localized administration, (3) remodel the microenvironment by engulfing cancer cells and presenting antigens to recruit T-cells, (4) scale via short, high-yield ex vivo manufacturing protocols for primary macrophages.
- **CALYM-001** (glioblastoma) is the lead intracranial program, listed at **in vivo validation** with **pre-IND** as the next milestone.
- **CALYM-002** (melanoma brain metastasis) is a platform-extension program in **early discovery**.
- The site states the company has **robust in-vitro and in-vivo datasets** and a **scalable ex-vivo production base**, and offers secure data-room access to qualified institutional investors and strategic partners for seed-financing discussions.

## Reliability Notes

This is an official company marketing site. Preclinical performance, manufacturing yields, regulatory timelines, and financing status are company assertions until confirmed in peer-reviewed publications, IND filings, or independent investor disclosures. The site does not name founders, investors, or academic lab origins on the pages reviewed.

## Related Pages

- [CaLycia Biosciences](calycia-biosciences.md)